Aptivus and Viracept drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Aptivus (tipranavir) and Viracept (nelfinavir mesylate). Common drug interactions include drug resistance among females and emotional distress among males.

The phase IV clinical study analyzes what interactions people have when they take Aptivus and Viracept. It is created by eHealthMe based on reports of 42 people who take the same drugs from the FDA, and is updated regularly.

What is Aptivus?

Aptivus has active ingredients of tipranavir. eHealthMe is studying from 1,060 Aptivus users. Check the latest studies of Aptivus.

What is Viracept?

Viracept has active ingredients of nelfinavir mesylate. It is often used in hiv infection. eHealthMe is studying from 6,399 Viracept users. Check the latest studies of Viracept.

On Aug, 09, 2026

42 people who take Aptivus and Viracept together, and have interactions are studied.

What are the common drug interactions of Aptivus and Viracept, by gender? *:

female:

Drug resistance (reduction in effectiveness of a drug)
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Asthenia (weakness)
Bone density decreased
Depression
Emotional disorder
Emotional distress
Mobility decreased (ability to move is reduced)
Pain

male:

Emotional distress
Kaposi's sarcoma (a tumour caused by human herpes virus)
Drug ineffective
Neoplasm progression (growth of tumour)
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Pyrexia (fever)
Chronic kidney disease
Decreased activity
Osteoporosis (bones weak and more likely to break)

What are the common drug interactions of Aptivus and Viracept, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Drug resistance (reduction in effectiveness of a drug)

10-19:

n/a

20-29:

n/a

30-39:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Emotional distress
Pain
Renal failure (kidney dysfunction)
Bone density decreased
Chronic kidney disease
Decreased activity
Depression
Fatigue (feeling of tiredness)

40-49:

Hypertension (high blood pressure)
Ileus (a painful obstruction of the ileum or other part of the intestine)
Ill-defined disorder
Neutropenia (an abnormally low number of neutrophils)
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Bone density decreased
Chronic kidney disease
Decreased activity
Depression

50-59:

Kaposi's sarcoma (a tumour caused by human herpes virus)
Dysuria (painful or difficult urination)
Immunodeficiency
Lymphoedema (localized fluid retention and tissue swelling)
Multiple-drug resistance
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Skin lesion
Urinary tract infection
Drug ineffective
Neoplasm progression (growth of tumour)

60+:

Emotional distress
Pain
Anxiety
Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
Osteoporosis (bones weak and more likely to break)
Renal failure (kidney dysfunction)
Drug ineffective
Dyslipidaemia (abnormal amount of lipids)
Dysuria (painful or difficult urination)
Fracture

What are the existing conditions these people have? *

Kaposi's Sarcoma (a tumour caused by human herpes virus): 18 people, 42.86%
Pain: 8 people, 19.05%
High Blood Pressure: 8 people, 19.05%
High Blood Cholesterol: 7 people, 16.67%
Diabetes: 5 people, 11.90%
Asthma: 5 people, 11.90%
Bacterial Infection: 4 people, 9.52%
Viral Infection: 3 people, 7.14%
Urinary Retention (the inability to completely or partially empty the bladder): 3 people, 7.14%
Insomnia (sleeplessness): 3 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Aptivus and Viracept?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously